The promise
and the potential
to effectively
treat cancer

The promise
and the potential
to effectively
treat cancer
Download Investor Presentation

Latest News & Events

2 December 2021

KOL Webinar on CD47 Therapeutics Dec. 2nd, 2021
23 November 2021

KAHR to Host Key Opinion Leader Webinar on the Potential of CD47 Therapeutics for the...

Press releases

2 September 2021

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers

More
16 June 2021

KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline

More
26 May 2021

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers

More
1 April 2021

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy

More
12 November 2020

KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

More
15 October 2020

KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board

More
12 October 2020

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

More
5 October 2020

KAHR Announces Two Key Appointments to Strengthen Leadership Team

More
12 August 2020

KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors

More
25 February 2020

KAHR Medical Raises $18 Million in Private Funding Round

More
9 September 2020

KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients

More
1 2 3 4
Company Highlights

Novel Technology

Novel MIRP™ technology to generate a family of immuno-recruitment drug platforms for multiple cancers

Promising results

Robust preclinical results
Ongoing Phase I/II for solid tumors
Collaboration with ROCHE to combine with Atezolizumab

Active Pipeline

DSP-107 - Phase I/II
DSP-502 and DSP-216 - IND 2023
Multiple future candidates in R&D

Growing market

Immuno-therapeutics market
estimated at
$56.5B by 2025

Solid IP Portfolio

12 families
2 granted patents in US and ROW
10 pending patents worldwide

Strong Leadership

Seasoned management team and KOL support: technology inventor, Prof. Mark Tykocinski, Dean of the School of Medicine and Provost, Jefferson University
Get in Touch
KAHR 1 Kiryat Hadassah JBP Bldg. POB 9779, Jerusalem, 9109701, Israel T. +972.73.7969196 info@kahr-medical.com